Cargando…

Nomogram to predict cause‐specific mortality in extensive‐stage small cell lung cancer: A competing risk analysis

BACKGROUND: Small‐cell lung cancer (SCLC) is one of the most aggressive types of lung cancer. The prognosis for SCLC patients depends on many factors. The intent of this study was to construct a nomogram model to predict mortality for extensive‐stage SCLC. METHODS: Original data was collected from t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Jia, Zheng, Qiwen, An, Tongtong, Zhao, Jun, Wu, Meina, Wang, Yuyan, Zhuo, Minglei, Li, Jianjie, Zhao, Xinghui, Yang, Xue, Jia, Bo, Chen, Hanxiao, Dong, Zhi, Wang, Jingjing, Chi, Yujia, Zhai, Xiaoyu, Wang, Ziping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718022/ https://www.ncbi.nlm.nih.gov/pubmed/31318178 http://dx.doi.org/10.1111/1759-7714.13148

Ejemplares similares

Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis
por: Li, Jianjie, et al.
Publicado: (2020)

Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database
por: Zhuo, Minglei, et al.
Publicado: (2019)

A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database
por: Jia, Bo, et al.
Publicado: (2020)

Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I–IIIA non-small cell lung cancer patients
por: Jia, Bo, et al.
Publicado: (2021)

Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database
por: Wang, Yuyan, et al.
Publicado: (2020)

Survival comparison of right and left side non‐small cell lung cancer in stage I–IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis
por: Jia, Bo, et al.
Publicado: (2019)

Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
por: Li, Jianjie, et al.
Publicado: (2021)

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
por: Chen, Hanxiao, et al.
Publicado: (2022)

Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients
por: Wang, Yida, et al.
Publicado: (2021)

Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience
por: Wang, Lu, et al.
Publicado: (2020)

Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma
por: Zhong, Jia, et al.
Publicado: (2018)

Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma
por: Li, Junfeng, et al.
Publicado: (2023)

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study
por: Yang, Xue, et al.
Publicado: (2021)

Optimal first‐line treatment for advanced thymic carcinoma
por: Yang, Xue, et al.
Publicado: (2019)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
por: Jia, Bo, et al.
Publicado: (2020)

放Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification
por: Jia, Bo, et al.
Publicado: (2021)

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer
por: Lv, Chunxin, et al.
Publicado: (2018)

ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane‐based chemotherapy
por: Zhong, Jia, et al.
Publicado: (2019)

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma
por: Wang, Shuhang, et al.
Publicado: (2020)

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
por: Wang, Zhijie, et al.
Publicado: (2014)

Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients
por: Zhuo, Minglei, et al.
Publicado: (2020)

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
por: Duan, Jianchun, et al.
Publicado: (2015)

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
por: Bai, Hua, et al.
Publicado: (2013)

Characterization of Lung and Oral Microbiomes in Lung Cancer Patients Using Culturomics and 16S rRNA Gene Sequencing
por: Sun, Yifan, et al.
Publicado: (2023)

Significant Upregulation of HERV-K (HML-2) Transcription Levels in Human Lung Cancer and Cancer Cells
por: Yang, Caiqin, et al.
Publicado: (2022)

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
por: Zhu, Jian, et al.
Publicado: (2012)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer
por: Wang, Shuhang, et al.
Publicado: (2013)

Impact of age on adjuvant chemotherapy after radical resection in patients with non–small cell lung cancer
por: Zhai, Xiaoyu, et al.
Publicado: (2016)

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer
por: Yang, Xue, et al.
Publicado: (2016)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
por: Wang, Shuhang, et al.
Publicado: (2015)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Nomogram Predicts the Role of Primary Tumor Surgery on De Novo Stage-IV Breast Cancer Patients: A SEER-Based Competing Risk Analysis Model
por: Cui, Hanxiao, et al.
Publicado: (2022)

Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study
por: Xing, Ziping, et al.
Publicado: (2022)

Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma
por: Chen, Xiaoyuan, et al.
Publicado: (2021)

Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non‐small cell lung cancer in a single center
por: Zhu, Yixiang, et al.
Publicado: (2016)

Nomograms for Differentiated Thyroid Carcinoma Patients Based on the Eighth AJCC Staging and Competing Risks Model
por: Li, Chengzhuo, et al.
Publicado: (2021)

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer
por: Duan, Jianchun, et al.
Publicado: (2017)

A nomogram for predicting the risk of sepsis in patients with acute cholangitis
por: Liu, Qingqing, et al.
Publicado: (2019)

Evaluating overall survival and competing risks of survival in patients with early‐stage breast cancer using a comprehensive nomogram
por: Xu, Yan‐Bo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fg7b403nffaj1atkdj8join5i3